ORTX Orchard Therapeutics


Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On June 16, 2021, Orchard Therapeutics plc (the “Company”) held its 2021 Annual General Meeting (the “Annual General Meeting”). At the Annual General Meeting, all the resolutions set out in the Notice of Annual General Meeting (the “Notice”) sent to shareholders and filed in the Company’s definitive proxy statement on Schedule 14A with the U.S. Securities and Exchange Commission on April 28, 2021 (the “Proxy Statement”) were duly proposed and passed.

The matters presented for a vote, which are described in additional detail in the Notice and Proxy Statement, and the related results of each resolution are listed below. Votes “Withheld” constitute abstentions.

Ordinary ResolutionsForAgainstWithheld
To re-elect Charles A. Rowland, Jr. as a director57,493,0188,840,35526,368
To re-elect Joanne T. Beck as a director63,363,1992,967,71128,831
To re-appoint PricewaterhouseCoopers LLP, a United Kingdom entity, as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders66,282,56754,06123,113
To ratify the appointment of PricewaterhouseCoopers LLP, a Delaware limited liability partnership, as the Company’s independent registered public accounting firm, for the fiscal year ending December 31, 202166,299,90753,4726,362
To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 202166,281,85465,19212,695
To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2020 and to note that the Company’s directors do not recommend the payment of any dividend for the year ended December 31, 202066,264,12878,06217,551
To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers for the year ended December 31, 202062,846,4113,441,98971,341
To receive and approve on an advisory basis the Company’s U.K. statutory directors’ remuneration report for the year ended December 31, 202062,998,3483,299,94761,446
To authorize the Board of Directors generally and unconditionally to allot shares pursuant to Section 551 of the Companies Act 2006 (the “Act”) or to grant rights to subscribe for or to convert any security into shares of the Company up to a maximum aggregate nominal amount of £13,023,851.5062,241,3373,969,545148,859
Special Resolutions
Subject to the passing of Resolution 9, to empower the Board of Directors to allot equity securities, under Section 570 of the Act as if Section 561(1) of the Act did not apply to such allotment up to a maximum aggregate nominal amount of £13,023,851.5053,305,94012,903,607150,194